[{"id":"000c9e91-0d80-4e40-954a-f0c80b85aaff","acronym":"","url":"https://clinicaltrials.gov/study/NCT03423992","created_at":"2021-01-18T16:53:23.130Z","updated_at":"2024-07-02T16:36:29.027Z","phase":"Phase 1","brief_title":"Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas","source_id_and_acronym":"NCT03423992","lead_sponsor":"Xuanwu Hospital, Beijing","biomarkers":" HER-2 • IL13RA2","pipe":"","alterations":" ","tags":["HER-2 • IL13RA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anti-EphA2 CAR-T therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/02/2018","start_date":" 03/02/2018","primary_txt":" Primary completion: 01/30/2023","primary_completion_date":" 01/30/2023","study_txt":" Completion: 01/30/2023","study_completion_date":" 01/30/2023","last_update_posted":"2021-06-15"}]